Pancreatic cancer is the fourth most common cause of cancer deaths in the United States with over 42,000 diagnosed with this disease every year. The prognosis is extremely grim for affected patients with <5% chance of survival within 5 years. The disappointing performance of current treatment modalities makes it imperative to investigate alternative strategies against pancreatic cancer. Combinatorial chemoprevention using low doses of drugs has the potential to provide an answer in terms of arresting this fast-spreading disease even before it is initiated. Aspirin, curcumin and sulforaphane have recently received significant attention as chemopreventive agents, however, no group has investigated a combinatorial effect of these agents despite recent evidence of synergistic activity of many promising chemopreventive agents when administered in combination. Also, there is limited data in literature as to the optimal chemopreventive combinations, doses, efficacy, side effects and an ideal formulation strategy to deliver these chemopreventive agents against pancreatic cancer. The formulation strategy for pancreatic drug delivery is important to consider in order to elicit any type of a meaningful therapeutic response. Nanotechnology-based drug delivery systems are currently being evaluated to deliver chemopreventive combinations that would lower the doses with lesser chance of toxic side effects, while maintaining efficacy. The application of such a system has never been studied in pancreatic cancer. Thus, the overall goal of this pilot study is to develop an effective, low dose, novel combination of chemopreventive agents delivered using a unique nanotechnology-based delivery system for the prevention of pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
1R03CA153812-01A1
Application #
8115727
Study Section
Special Emphasis Panel (ZCA1-SRLB-F (J1))
Program Officer
Perloff, Marjorie
Project Start
2011-02-17
Project End
2013-01-31
Budget Start
2011-02-17
Budget End
2012-01-31
Support Year
1
Fiscal Year
2011
Total Cost
$74,500
Indirect Cost
Name
Western University of Health Sciences
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
093373694
City
Pomona
State
CA
Country
United States
Zip Code
91766
Grandhi, B Karthik; Thakkar, Arvind; Wang, Jeffrey et al. (2013) A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer Prev Res (Phila) 6:1015-1025
Thakkar, Arvind; Sutaria, Dhruvitkumar; Grandhi, B Karthik et al. (2013) The molecular mechanism of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer. Oncol Rep 29:1671-7
Sutaria, Dhruvitkumar; Grandhi, Balagangadhar Karthik; Thakkar, Arvind et al. (2012) Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen. Int J Oncol 41:2260-8